Market revenue in 2020 | USD 40,419.9 million |
Market revenue in 2028 | USD 69,048.3 million |
Growth rate | 6.9% (CAGR from 2020 to 2028) |
Largest segment | Neurodegenerative diseases |
Fastest growing segment | Neurodegenerative Diseases |
Historical data covered | 2018 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Neurodegenerative diseases was the largest segment with a revenue share of 40.1% in 2020. Horizon Databook has segmented the North America central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
North America held the largest share of the CNS therapeutics market. Presence of highly developed healthcare infrastructure coupled with better reimbursement policies and high awareness regarding available novel treatment options are anticipated to drive the regional market.
Rise in number of initiatives undertaken by key players to develop novel therapies for different applications in central nervous system disorders is also expected to impel regional market share. The growing incidence of mental and neurodegenerative diseases.
Such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, & epilepsy, is fueling demand for CNS therapeutics in the region. For instance, about 2.5 million people have been diagnosed with multiple sclerosis worldwide, out of which, around 20% live in the North American region.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America central nervous system therapeutic market , including forecasts for subscribers. This continent databook contains high-level insights into North America central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account